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SELF-ARCHIVING VERSION 
 
Anorexia Nervosa Genetics Initiative (ANGI) Identifies Eight Loci Associated with 
Anorexia Nervosa 
 
Characterized primarily by extremely low BMI, anorexia nervosa (AN) is a complex, serious, 
and commonly misunderstood illness1. AN predominantly affects women, carries high risks of 
mortality from cachexia and suicide2,3, and treatment outcomes remain unacceptably poor4. 
No medications exist that are effective and improved treatments will likely depend on deeper 
understanding of the core biology of this illness5. Genetic factors clearly play an etiological 
role with twin-based heritability estimates of 50-60%6. Combining samples from the Anorexia 
Nervosa Genetics Initiative (ANGI)7,8 and the Eating Disorders Working Group of the 
Psychiatric Genomics Consortium (PGC-ED), we conducted a genome-wide association study 
(GWAS) meta-analysis of clinical, population, and volunteer cohorts and identified 8 
independent genome-wide significant loci in 16,991 AN cases and 56,059 controls. Our 
analyses reveal that the genetic architecture of AN mirrors its clinical features and 
comorbidities, with high genetic correlations with obsessive-compulsive disorder (OCD), major 
depressive disorder (MDD), and anxiety disorders. Notably, the etiology of AN had the 
strongest metabolic and anthropometric genetic components of any psychiatric disorder yet 
examined. Specifically, we observed strong negative genetic correlations between AN and 
fasting insulin levels, body fat percentage, and BMI as well as a strong positive genetic 
correlation between AN and high-density lipoprotein cholesterol. These results support a 
broadened reconceptualization of AN etiology, underscoring that AN should be considered as 
both a psychiatric and metabolic disorder. Deeper understanding of the metabolic component 
is a critical next step and attention to both components may be necessary to improve treatment 
efficacy. 
 
AN affects 0.9-4% of women and 0.3% of men with high medical and psychiatric morbidity9,10. 
Mortality rates associated with AN are elevated fivefold and are the highest of any psychiatric 
disorder11. There are few effective psychotherapeutic interventions, especially for adults, and 
pharmacological interventions—typically directed toward management of secondary 
symptoms—are minimally effective for the core features of AN5. Using genetics to elucidate the 
biological basis of AN could spur the development of effective treatments and reduce mortality. 
 
Genetic factors play a role in AN6. The 2017 PGC-ED GWAS of 3,495 cases and 10,982 
controls, estimated the common genetic variant-based heritability as ~20%, identified the first 
genome-wide significant locus, and reported significant genetic correlations (rg) between AN and 
psychiatric and metabolic phenotypes12. Genetic correlations are not affected by reverse 
causation, although they may be mediated13, and these results hinted at a role for metabolic 
etiological factors. In this study, we quadrupled the number of AN cases by combining the 
Anorexia Nervosa Genetics Initiative (ANGI)7,8, the Genetic Consortium for Anorexia 
Nervosa/Wellcome Trust Case Control Consortium 314, and the UK Biobank15. Our goals were 
to identify convincing genotype-phenotype associations and elucidate the biology underlying 
AN. 
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Our GWAS meta-analysis included 33 datasets comprising 16,991 cases and 56,059 controls of 
European ancestry from 17 countries (Supplementary Tables 1-4). As typically seen in large 
GWAS of complex traits, we observed inflation of the test statistics (λ = 1.22, Supplementary 
Figure 1) consistent with polygenicity but no evidence of significant population stratification 
(See Supplementary Results). Meta-analysis results were completed for the autosomes and the 
X chromosome and were clumped to define eight independent genetic loci exceeding genome-
wide significance (P < 5 × 10-8; Figure 1; Table 1) with consistent effects across cohorts. Seven 
of the loci have been associated in GWAS of other phenotypes, including autoimmune disorders, 
educational attainment, age at menarche, HDL cholesterol, and BMI (Supplementary Table 5). 
Supplementary Tables 6-8 describe annotations of genes within each locus. Supplementary 
Table 9 reports a look-up restricted to the single-gene loci.  
 
The top single nucleotide polymorphism (SNP) was rs9821797 (P = 4.53 × 10-15; odds ratio 
(OR) = 1.17; 95% confidence interval (CI): 1.13-1.22) in a locus on chromosome 3 with reported 
associations including autoimmune diseases, educational attainment, and HDL cholesterol. The 
locus contains >50 genes (see Supplementary Table 6 and Supplementary Table 8). The 
second most significant SNP (rs6589488; chr 11; P = 9.57 × 10-11; OR = 1.13; 95% CI: 1.09-
1.18) has been associated with BMI, and maps to CADM1 (cell adhesion molecule 1), a member 
of the immunoglobulin superfamily with hypothesized roles in behavioral phenotypes16. The 
third locus (rs2287348; chr 2; P = 4.68 × 10-9; OR = 1.11; 95% CI: 1.07-1.15) maps on to seven 
genes and has previously been associated with BMI. The fourth locus (rs12415589; chr 10; P = 
1.80 × 10-8; OR = 1.08; 95% CI: 1.05-1.11) maps on to MGMT (O6-methylguanine–DNA 
methyltransferase) which is involved in DNA repair17. The fifth locus (rs370838138; chr 5; P = 
1.84 × 10-8; OR = 1.08, 95% CI: 1.05-1.11) is intergenic and not associated with any other trait. 
The sixth locus (rs9874207; chr 3; P = 2.44 × 10-8; OR = 1.08; 95% CI: 1.05-1.12) maps on to 
FOXP1 (forkhead box P1), rare mutations which cause intellectual disability (OMIM #613670) 
and has been associated with esophageal adenocarcinoma. The seventh locus (rs13125932; chr 4; 
P = 4.64 × 10-8; OR = 1.08; 95% CI: 1.05-1.10) is intergenic. The eighth locus (rs34816338; chr 
1; P = 4.98 × 10-8; OR = 1.08; 95% CI: 1.05-1.12) was not previously associated. For detailed 
references see Supplementary Results. The previous locus reported in Duncan et al.12 on 
12q13.2 did not reach genome-wide significance (P = 8.85 × 10-6); however, between-cohort 
heterogeneity was apparent (I2 = 53.74; Supplementary Results and Supplementary Figure 2).  
 
Similar to the work by Won et al.18, we used Hi-C data generated from human adult brain to 
identify genes implicated by three-dimensional functional interactomics (Methods and 
Supplementary Figure 3 a-h). These Hi-C data (N = 3, anterior temporal cortex) contain 509K 
high-confidence chromatin interactions (P Giusti-Rodríguez and PF Sullivan, personal 
communication). First, three multigenic loci were highly complex with many brain-expressed 
genes and a dense pattern of chromatin interactions precluding the identification of any single 
gene (locus 1, chr3:47.5-51.6 Mb, P = 4.53 × 10-15; locus 3, chr2:53.8-54.3 Mb, P = 4.7 × 10-9; 
locus 8, chr1:192.8-193.4, P = 4.97 × 10-8). Second, functional interactomic data from brain 
confirmed that the two single-gene associations were to the genes in which the associations were 
located. For locus 2 (chr11:114.9-115.4 Mb, P = 9.57 × 10-11), the vast majority of chromatin 
interactions were from the association region to CADM1 (936 of 1051 interactions). For locus 4 
(chr10:131.2-131.4 Mb, P = 1.80 × 10-8), an intragenic association in MGMT, the only chromatin 
interactions were to the same gene. Third, for the intergenic associations, locus 5 (chr5:24.9-
 3 
25.37 Mb, P = 1.83 × 10-8) had chromatin interactions with CDH10 (cadherin 10) suggesting a 
functional connection, and all 79 chromatin interactions for locus 6 (chr3:70.6-71.0, P =2.43 × 
10-8) were to FOXP1. Locus 7 (chr4:58.0-58.2, P =4.64 × 10-8) had no clear connection. These 
data suggest that CADM1, MGMT, CDH10, and FOXP1 may play a role in the etiology of AN. 
 
Conditional and joint analysis (COJO) of our genome-wide significant SNPs confirm their 
independence19 (Supplementary Table 10 and Methods). Supplementary Table 11 shows the 
results of multi-trait analysis (mtCOJO)20 conditioning our genome-wide significant SNPs on 
variants that were associated in GWASs of BMI, HDL, type 2 diabetes, schizophrenia, 
neuroticism, and education years. Five loci appear to be independent. However, conditioning on 
neuroticism revealed one additional genome-wide significant hit on chromosome 1 (rs10747478, 
chr 1; P = 3.87 × 10-8; OR = 1.08; 95% CI: 1.05-1.11). The loci on chromosomes 1, 4, and 10 
may not be independent of the associations identified by the GWAS that were used for the 
conditioning. 
 
The liability-scale SNP heritability (SNP-h2) of these results using linkage disequilibrium score 
regression (LDSC)21 was 13% (s.e. = 1%) assuming a population prevalence of 0.9%, supporting 
the polygenic nature of AN. Polygenic risk score (PRS) analyses were conducted using a leave-
one-dataset-out approach and indicated that the PRS captures ~1.7% (P = 1.62 × 10-13) of the 
phenotypic variance on the liability scale. We did not observe differences in polygenic 
architecture between males and females with AN (male: N = 447 cases N = 20,347 controls) or 
between binge eating and non-binge eating subtypes of AN (Methods, Supplementary Results, 
Supplementary Figure 4-5); however, these are tentative results and await larger samples and 
increased power before conclusions can be drawn. 
 
We then tested SNP-based genetic correlations (SNP-rg) with a wide range of external traits and 
disorders using bivariate LDSC21. Significant SNP-rg surpassing Bonferroni correction fell into 
five categories: psychiatric and personality traits; physical activity; anthropometric traits; 
metabolic traits; and educational attainment (Figure 2, Supplementary Tables 12-13). Positive 
SNP-rgs were observed with OCD (SNP-rg ± s.e. = 0.45 ± 0.07; P = 1.12 × 10
-9), MDD (0.25 ± 
0.06; P = 8.77 × 10-5), anxiety disorders (0.25 ± 0.04; P = 8.39 × 10-9), schizophrenia (0.24 ± 
0.02; P = 1.67 × 10-22), and bipolar disorder (0.19 ± 0.05; P = 8.65 × 10-5). This pattern reflects 
observed comorbidities in clinical and epidemiological studies22,23. The positive SNP-rg with 
physical activity (0.17 ± 0.04; P = 4.78 × 10-5) is a new finding that encourages further 
exploration of the perplexing and difficult to treat symptom of pathologically elevated activity in 
AN24. We observed significant positive SNP-rg with educational attainment (0.21 ± 0.04; P = 
7.73 × 10-9) and related constructs, but no significant rg with IQ. Expanding previous 
observations12, we observed a palette of metabolic and anthropometric genetic correlations with 
AN far more pronounced than that seen in other psychiatric disorders. We observed significant 
negative SNP-rg with fat mass (-0.33 ± 0.03; P = 2.74 × 10
-24), fat free mass (-0.12 ± 0.03; P = 
4.09 × 10-5), BMI (-0.31 ± 0.03; P = 5.38 × 10-23), obesity (-0.22 ± 0.04; P = 1.77 × 10-10), 
fasting insulin (-0.25 ± 0.06; P = 3.42 × 10-5), insulin resistance (-0.29 ± 0.07; P = 6.74 × 10-5), 
type 2 diabetes (-0.22 ± 0.05; P = 2.75 × 10-5), and leptin (-0.26 ± 0.07; P = 1.00 × 10-4) along 
with a significant positive SNP-rg with HDL cholesterol (0.22 ± 0.04; P = 4.34 × 10
-8).  
 
 4 
With an increased number of GWAS loci for AN, systems biology analyses of our results 
revealed interesting albeit preliminary results. Firstly, partitioned heritability analysis showed, as 
with other GWAS25, enrichment of SNP-h2 in conserved regions (fold enrichment = 25.0, s.e. 
3.3, P = 1.12 × 10-11; Supplementary Figure 6)26. Cell type group-specific annotations revealed 
that the overall SNP-h2 is significantly enriched for CNS tissue (Supplementary Figure 7). 
Second, we evaluated whether genes associated with AN were enriched in specific pathways, 
tissues or cell types (Methods) using MAGMA (Supplementary Table 14)27. One biological 
pathway was significant, but its p-value was very close to the significance threshold 
(Supplementary Table 15): GO:positive_regulation_of_embryonic_development (Gene 
Ontology, 32 genes, P = 6.31 × 10-6). Genes associated with AN were enriched for expression 
specificity in the majority of brain tissues in GTEx, particularly the cerebellum and cerebellar 
hemispheres (Supplementary Figure 8), which have the highest proportion of neurons28. 
Similarly, among specific cell types, significant enrichment was found for pyramidal neurons 
from the CA1 region of the hippocampus (Supplementary Figure 9). Twenty-nine genes were 
predicted to be tissue-specific differentially expressed in 29 GTEx tissues (Supplementary 
Table 16) with MGMT on chromosome 10 being predicted to be downregulated in the caudate. 
We interpret these results cautiously, but they represent the first indications of the specific 
pathways, tissues, and cell types that mediate the genetic risk for AN). with MGMT on 
chromosome 10 being predicted to be downregulated in the caudate. We interpret these results 
cautiously, but they represent the first indications of the specific pathways, tissues, and cell types 
that mediate the genetic risk for AN. 
 
In conclusion, we report multiple genetic loci with promising clinical and functional analyses 
and enrichments. The most striking finding is a strengthened pattern of both psychiatric and 
metabolic/anthropometric genetic correlations, which inspire new lines of inquiry into the 
metabolic and anthropometric components of AN etiology and disorder maintenance.  
 
Low BMI and associated traits have traditionally been viewed as symptoms of AN. This 
perspective has failed to yield any interventions that reliably lead to sustained weight gain and 
recovery. Our results suggest that metabolic factors may play an etiological role in AN or that 
many of the same genes may influence both AN and metabolic traits. This was hypothesized 
decades ago29, but is now supported by genetic data. Clinically, AN is nearly universally 
characterized by exceptional difficulty in maintaining a healthy BMI (even after therapeutic 
renourishment) in the face of an overwhelming biological and psychological pull toward low 
weight. Addressing metabolic rather than purely psychological drivers of this process may open 
new avenues for treatment and inspire novel biological approaches to understanding and treating 
this frequently lethal illness. Genomic discovery in AN is underway and will accelerate with 
increasing sample size. 
 
URLs. LDhub, http://ldsc.broadinstitute.org; LDSC, https://github.com/bulik/ldsc; MAGMA, 
http://ctg.cncr.nl/software/magma; PRSice, https://github.com/choishingwan/PRSice/wiki; 
Ricopili, https://github.com/Nealelab/ricopili/tree/master/rp_bin; UK Biobank, 
http://www.ukbiobank.ac.uk  
 
METHODS 
Methods are available in the online version of the paper. 
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